Alkermes (ALKS)
(Delayed Data from NSDQ)
$26.59 USD
-0.52 (-1.92%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $26.52 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.59 USD
-0.52 (-1.92%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $26.52 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Compared to Estimates, Alkermes (ALKS) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exploring Analyst Estimates for Alkermes (ALKS) Q4 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Alkermes (ALKS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Incyte's (INCY) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition recently.
Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Alkermes (ALKS) settling at $26.70, representing a -1.26% change from its previous close.
Alkermes (ALKS) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw Alkermes (ALKS) settling at $26.94, representing a -0.41% change from its previous close.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why Alkermes (ALKS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alkermes (ALKS) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Alkermes (ALKS) closed the most recent trading day at $27.74, moving -1% from the previous trading session.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Alkermes (ALKS) closed at $28.20, indicating a +0.93% shift from the previous trading day.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes (ALKS) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Alkermes (ALKS) reachead $27.92 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.
Why Is Alkermes (ALKS) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition
by Zacks Equity Research
Alkermes' (ALKS) growth is being driven by the sale of its proprietary products, Vivitrol, Aristada and Lybalvi. However, stiff competition in the target market remains an overhang.
Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View
by Zacks Equity Research
Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales. Stock price drops 5% post the announcement.
CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected
by Zacks Equity Research
CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.
Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
by Zacks Equity Research
Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.
Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.
Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. Shares fall.
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.